Daniel Schramek
Overview
Explore the profile of Daniel Schramek including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
68
Citations
3167
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Panzeri I, Fagnocchi L, Apostle S, Tompkins M, Wolfrum E, Madaj Z, et al.
Nat Cancer
. 2025 Jan;
6(2):385-403.
PMID: 39856421
Mutations in cancer risk genes increase susceptibility, but not all carriers develop cancer. Indeed, while DNA mutations are necessary drivers of cancer, only a small subset of mutated cells go...
2.
Drucker K, Jenkins R, Schramek D
Cancer Res
. 2025 Jan;
85(5):836-837.
PMID: 39786420
Isocitrate dehydrogenase (IDH)-mutant low-grade gliomas are slow-growing brain tumors that frequently progress to aggressive high-grade gliomas that have dismal outcomes. In a recent study, Wu and colleagues provide critical insights...
3.
Uijttewaal E, Lee J, Sell A, Botay N, Vainorius G, Novatchkova M, et al.
Nat Biotechnol
. 2024 Dec;
PMID: 39681701
Pooled genetic screening with CRISPR-Cas9 has enabled genome-wide, high-resolution mapping of genes to phenotypes, but assessing the effect of a given genetic perturbation requires evaluation of each single guide RNA...
4.
Su P, Liu Y, Chen T, Xue Y, Zeng Y, Zhu G, et al.
Nat Genet
. 2024 Sep;
56(9):1890-1902.
PMID: 39227744
Functional genomic screens in two-dimensional cell culture models are limited in identifying therapeutic targets that influence the tumor microenvironment. By comparing targeted CRISPR-Cas9 screens in a two-dimensional culture with xenografts...
5.
MacLeod G, Molaei F, Haider S, Almeida M, Lin S, Kushida M, et al.
Cancer Res
. 2024 Aug;
84(23):3967-3983.
PMID: 39186687
Glioblastoma (GBM) is the most common and lethal primary brain tumor in adults and is driven by self-renewing glioblastoma stem cells (GSC) that persist after therapy and seed treatment-refractory recurrent...
6.
Visvanathan A, Saulnier O, Chen C, Haldipur P, Orisme W, Delaidelli A, et al.
Cell
. 2024 Jul;
187(17):4733-4750.e26.
PMID: 38971152
We identify a population of Protogenin-positive (PRTG) MYC NESTIN stem cells in the four-week-old human embryonic hindbrain that subsequently localizes to the ventricular zone of the rhombic lip (RL). Oncogenic...
7.
Martinez S, Wu S, Geuenich M, Malik A, Weber R, Woo T, et al.
Nat Commun
. 2024 Jun;
15(1):5266.
PMID: 38902237
Functionally characterizing the genetic alterations that drive pancreatic cancer is a prerequisite for precision medicine. Here, we perform somatic CRISPR/Cas9 mutagenesis screens to assess the transforming potential of 125 recurrently...
8.
Lu Y, Cho T, Mukherjee S, Suarez C, Gonzalez-Foutel N, Malik A, et al.
Mol Syst Biol
. 2024 Apr;
20(6):719-740.
PMID: 38580884
Tumor suppressor p53 (TP53) is frequently mutated in cancer, often resulting not only in loss of its tumor-suppressive function but also acquisition of dominant-negative and even oncogenic gain-of-function traits. While...
9.
Poirson J, Cho H, Dhillon A, Haider S, Imrit A, Lam M, et al.
Nature
. 2024 Mar;
628(8009):878-886.
PMID: 38509365
Targeted protein degradation and stabilization are promising therapeutic modalities because of their potency, versatility and their potential to expand the druggable target space. However, only a few of the hundreds...
10.
Adler N, Bahcheli A, Cheng K, Al-Zahrani K, Slobodyanyuk M, Pellegrina D, et al.
Sci Adv
. 2023 Nov;
9(44):eadh3083.
PMID: 37922356
Mutational signatures represent a genomic footprint of endogenous and exogenous mutational processes through tumor evolution. However, their functional impact on the proteome remains incompletely understood. We analyzed the protein-coding impact...